Reirradiation for recurrent medulloblastoma.

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Neuro-oncology

Background:

• Recurrent medulloblastoma (MB) after initial treatment is a highly lethal condition.
• Reirradiation is often avoided due to toxicity concerns and uncertain efficacy.
• Analyzing retreatment data can clarify the role and feasibility of reirradiation for recurrent MB.

Purpose of the Study:

• To evaluate the feasibility and outcomes of reirradiation in patients with recurrent medulloblastoma.
• To identify patient subgroups that may benefit most from reirradiation.
• To assess the toxicity profile of reirradiation in this patient population.

Main Methods:

• Retrospective analysis of 13 patients with recurrent medulloblastoma who received reirradiation.
• Detailed review of treatment history, radiation doses, sites, and patient outcomes.
• Survival analysis using Kaplan-Meier estimates and assessment of toxicity.

Main Results:

• Reirradiation was administered to various sites including posterior fossa, brain, and spine, with median cumulative doses up to 84 Gy.
• Five-year progression-free and overall survival rates were 48% and 65%, respectively.
• Patients without gross disease at reirradiation had an 83% rate of being without evidence of disease at follow-up; reirradiation was well-tolerated with minimal toxicity.

Conclusions:

• Reirradiation can be a feasible and potentially beneficial treatment for recurrent medulloblastoma.
• Patients achieving no evidence of disease after surgical re-resection appear to benefit most.
• Further investigation into reirradiation as part of multimodality therapy is warranted, considering factors like time between radiation courses and patient age.